Markets Maxim ups Fennec PT to $15 on PEDMARK approval Maxim Group raised its price target for Fennec Pharmaceuticals (NASDAQ:FENC) to $15 from $10, and maintained its “buy” rating, after FDA approval of PEDMARK, its formulation of sodium thiosulfate for the prevention of... September 29, 2022